Efficacy of cisplatin and lipoplatin™ in combined treatment with radiation of a colorectal tumor in nude mouse

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3005-3014

  Tippayamontri, Thititip ^a   Kotb, Rami ^b   Paquette, Benoit ^a   Sanche, Leon ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Chemotherapy; Cisplatin; Colorectal cancer; Concomitant therapy; Lipoplatin ; Radiotherapy

Indexed keywords

CISPLATIN; LIPOPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CHEMORADIOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

CHEMOTHERAPY; CISPLATIN; COLORECTAL CANCER; CONCOMITANT THERAPY; LIPOPLATIN™; RADIOTHERAPY;

ANIMALS; APOPTOSIS; BODY WEIGHT; CELL NUCLEUS; CHEMORADIOTHERAPY; CISPLATIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HCT116 CELLS; HUMANS; MALE; MICE; MICE, NUDE; PLATINUM; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883268502     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bao YH, Yuan XC, Wu JD, Zhang WJ and Jiang ZF: Cisplatin as a radiosensitizer in clinical practice: A pilot study. Tumori 77: 21-24, 1991.
2. Boidi Trotti A, Rovea P, Gabriele AM, Tseroni V, Fracchia F, Raiteri M, Tardy A, Valle A, Bertetto O and Nastasi U: The use of cisplatin as radiosensitizing agent in advanced tumors of the head and neck. Randomized study. Radiol Med 82: 504-507, 1991.
3. Asaka-Amano Y, Takiguchi Y, Yatomi M, Kurosu K, Kasahara Y, Tanabe N, Tatsumi K and Kuriyama T: Effect of treatment schedule on the interaction of cisplatin and radiation in human lung cancer cells. Radiat Res 167: 637-644, 2007.
4. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 358: 781-786, 2001.
5. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J and Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098, 2003.
6. Candelaria M, Garcia-Arias A, Cetina L and Duenas-Gonzalez A: Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 1: 15-31, 2006.
7. Begg AC: Cisplatin and radiation: Interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19: 1183-1189, 1990.
8. Gorodetsky R, Levy-Agababa F, Mou X and Vexler AM: Combination of cisplatin and radiation in cell culture: Effect of duration of exposure to drug and timing of irradiation. Int J Cancer 75: 635-642, 1998.
9. Eberhardt W, Pottgen C and Stuschke M: Chemoradiation paradigm for the treatment of lung cancer. Nat Clin Pract Oncol 3: 188-199, 2006.
10. Holding JD, Lindup WE, Bowdler DA, Siodlak MZ and Stell PM: Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck. Br J Clin Pharmacol 32: 173-179, 1991.
11. Lagrange JL, Bondiau PY, Tessier E, Chauvel P, Renee N, Etienne MC and Milano G: Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer. Int J Cancer 68: 452-456, 1996.
12. Terheggen PM, Emondt JY, Floot BG, Dijkman R, Schrier PI, den Engelse L and Begg AC: Correlation between cell killing by cis- diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res 50: 3556-3561, 1990.
13. Seiwert TY, Salama JK and Vokes EE: The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol 4: 86-100, 2007.
14. Boulikas T: Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a chemotherapy and antiangiogenesis drug. Cancer Therapy 5: 351-376, 2007.
15. Zheng Y, Hunting DJ, Ayotte P and Sanche L: Role of secondary low-energy electrons in the concomitant chemoradiation therapy of cancer. Phys Rev Lett 100: 198101-198104, 2008.
16. Tippayamontri T, Kotb R, Paquette B and Sanche L: Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model. Anticancer Res 32: 4395-4404, 2012.
17. Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H and Begg AC: Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: Lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol 61: 1075-1081, 2008.
18. Boulikas T, Pantos A, Bellis E and Christofis P: Designing platinum compounds in cancer: structures and mechanisms. Cancer Therapy 5: 537-583, 2007.
19. Koukourakis MI, Giatromanolaki A, Pitiakoudis M, Kouklakis G, Tsoutsou P, Abatzoglou I, Panteliadou M, Sismanidou K, Sivridis E and Boulikas T: Concurrent liposomal cisplatin (lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: A phase I/II study. Int J Radiat Oncol Biol Phys 78: 150-155, 2010.
20. Tippayamontri T, Kotb R, Paquette B and Sanche L: Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs 29: 1321-1327, 2011.
21. Paquette B and Little JB: In vivo enhancement of genomic instability in minisatellite sequences of mouse C3H/10T1/2 cells transformed in vitro by X-rays. Cancer Res 54: 3173-3178, 1994.
22. Charest G, Paquette B, Fortin D, Mathieu D and Sanche L: Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation. J Neurooncol 97: 187-193, 2010.
23. Hoffe SE, Shridhar R and Biagioli MC: Radiation therapy for rectal cancer: Current status and future directions. Cancer Control 17: 25-34, 2010.
24. Jorgensen TJ, Tian H, Joseph IB, Menon K and Frost D: Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol 59: 725-732, 2007.
25. Los G, Mutsaers PH, Ruevekamp M and McVie JG: The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett 51: 109-117, 1990.
26. Chaney SG, Gibbon GR, Schmidt W and Page JD: Carrier ligand effects in platinum-resistant cell line. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Howell SB (ed.). New York, Plenum Press, pp. 269-284, 1991.
27. Choy H and Macrae RM: Chemoradiation: Biological principles and perspectives. In: Chemoradiation in Cancer Therapy. Choy H (ed.). New Jersey, Humana Press, pp. 3-22, 2003.
28. Hall EJ and Giaccia AJ: Chemotherapeutic agents from the perspective of the radiation biologist. In: Radiobiology for the Radiologists. Philadelphia, Lippincott Williams and Wilkins Publishing, pp. 440-468, 2006.
29. Zimbrick JD, Sukrochana A and Richmond RC: Studies on radiosensitization of Escherichia coli cells by cis-platinum complexes. Int J Radiat Oncol Biol Phys 5: 1351-1354, 1979.
30. Dolling JA, Boreham DR, Brown DL, Raaphorst GP and Mitchel RE: Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat Res 433: 127-136, 1999.
31. Raaphorst GP, Leblanc M and Li LF: A comparison of response to cisplatin, radiation and combined treatment for cells deficient in recombination repair pathways. Anticancer Res 25: 53-58, 2005.
32. Lelieveld P, Scoles MA, Brown JM and Kallman RF: The effect of treatment in fractionated schedules with the combination of Xirradiation and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin. Int J Radiat Oncol Biol Phys 11: 111-121, 1985.
33. Diggle CP, Bentley J, Knowles MA and Kiltie AE: Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts. Nucleic Acids Res 33: 2531-2539, 2005.
34. Karve S, Werner ME, Sukumar R, Cummings ND, Copp JA, Wang EC, Li C, Sethi M, Chen RC, Pacold ME and Wang AZ: Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci USA 109: 8230-8235, 2012.
35. Dewit L: Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13: 403-426, 1987.
36. Ravaioli A, Papi M, Pasquini E, Marangolo M, Rudnas B, Fantini M, Nicoletti SV, Drudi F, Panzini I, Tamburini E, Gianni L and Pasini G: Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small cell lung cancer. J Chemother 21: 86-90, 2009.
37. Stathopoulos GP: Liposomal cisplatin: A new cisplatin formulation. Anticancer Drugs 21: 732-736, 2010.
38. Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K and Michalopoulou P: Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small cell lung cancer. Cancer Chemother Pharmacol 68: 945-950, 2011.
39. Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD and Cullen KJ: Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 46: 255-262, 2000.
40. Stathopoulos GP and Boulikas T: Lipoplatin formulation review article. J Drug Deliv 2012: 581363, 10 pages, 2012.
41. Gourdier I, Crabbe L, Andreau K, Pau B and Kroemer G: Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23: 7449-7457, 2004.
42. Mandic A, Hansson J, Linder S and Shoshan MC: Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278: 9100-9106, 2003.
43. Wang K, Lu J and Li R: The events that occur when cisplatin encounters cells. Coord Chem Rev 151: 53-88, 1996.
44. Boddapati SV, Tongcharoensirikul P, Hanson RN, D'Souza GG, Torchilin VP and Weissig V: Mitochondriotropic liposomes. J Liposome Res 15: 49-58, 2005.
45. Hori R, Okumura K and Yoshida H: Binding of basic drugs to rat lung mitochondria. Pharm Res 4: 142-146, 1987.